2026 Global: Chemotherapy-Induced Nausea And Vomiting (Cinv) Market -Competitive Review (2032) report
Description
The 2026 Global: Chemotherapy-Induced Nausea And Vomiting (Cinv) Market -Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for chemotherapy-induced nausea and vomiting (cinv) market by geography and historical trend. The scope of the report extends to sizing of the chemotherapy-induced nausea and vomiting (cinv) market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Merck & Co., GlaxoSmithKline (GSK), Heron Therapeutics, Helsinn Healthcare, and Novartis are among the leading companies shaping the Chemotherapy-Induced Nausea and Vomiting (CINV) market through approved therapies, combination regimens, and formulation innovations. Merck’s Emend (aprepitant/fosaprepitant) remains a cornerstone NK1-receptor antagonist used in both acute and delayed CINV prevention and is available in oral and IV forms. GSK, following its acquisition of Tesaro, markets rolapitant (Varubi) and has expanded its oncology supportive-care portfolio, positioning itself strongly in delayed-phase CINV management. Heron Therapeutics differentiated its offering with the extended-release granisetron formulation Sustol, providing multi-day control from a single administration and addressing adherence challenges in outpatient chemotherapy. Helsinn focuses on integrated supportive-care products and has a presence in palonosetron and other antiemetic classes that target 5‑HT3 pathways, complementing steroid and NK1 antagonist regimens favored in guideline-based prophylaxis. Novartis and its affiliated lines participate via branded and generic 5‑HT3 agents and supportive-care strategies, contributing to market breadth across hospital and retail channels and supporting combination regimen adoption.
Pfizer, Kyowa Kirin (and Ono as regional partners), Teva Pharmaceutical Industries, and Roche (including Sandoz/Generics affiliates) supply a mix of branded agents, generics, and hospital-focused formulations that sustain global access to CINV treatments. Pfizer’s broader oncology portfolio and acquisitions strengthen its role in supportive-care combinations and formulary presence, while Kyowa Kirin and Ono supply regionally significant antiemetics and collaborate on development of NK1/5‑HT3 combinations and novel delivery forms. Teva and Sandoz (Novartis’s generics arm) drive volume through ondansetron, granisetron, and other generic 5‑HT3 agents that lower cost barriers and enable guideline-concordant triple therapy in many health systems. Roche and its generics/partner channels play a complementary role by supplying IV formulations and hospital-oriented logistics that match oncology infusion workflows, supporting adoption of prophylactic regimens for highly and moderately emetogenic chemotherapy.
Emerging and specialty players such as Acacia Pharma, Camurus, and regional companies (Dr. Reddy’s, Sun Pharmaceutical, Aurobindo/Cipla, and Qilu) expand therapeutic options with novel formulations, transdermal systems, and targeted molecules that address breakthrough, delayed, and anticipatory CINV. Acacia’s IV amisulpride development and Camurus’s formulation work target refractory or rescue-use cases, while companies like Dr. Reddy’s, Sun Pharma, Aurobindo, and Cipla increase generic supply of 5‑HT3 antagonists and corticosteroids that underpin standard regimens in cost-sensitive markets. Startups and specialty biotech firms are also advancing non‑oral delivery (e.g., transdermal patches) and long‑acting depot approaches to reduce dosing complexity and improve multi‑day coverage, creating competitive pressure and partnership opportunities for incumbents across hospital, retail, and outpatient oncology settings.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for chemotherapy-induced nausea and vomiting (cinv) market by geography and historical trend. The scope of the report extends to sizing of the chemotherapy-induced nausea and vomiting (cinv) market market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
Merck & Co., GlaxoSmithKline (GSK), Heron Therapeutics, Helsinn Healthcare, and Novartis are among the leading companies shaping the Chemotherapy-Induced Nausea and Vomiting (CINV) market through approved therapies, combination regimens, and formulation innovations. Merck’s Emend (aprepitant/fosaprepitant) remains a cornerstone NK1-receptor antagonist used in both acute and delayed CINV prevention and is available in oral and IV forms. GSK, following its acquisition of Tesaro, markets rolapitant (Varubi) and has expanded its oncology supportive-care portfolio, positioning itself strongly in delayed-phase CINV management. Heron Therapeutics differentiated its offering with the extended-release granisetron formulation Sustol, providing multi-day control from a single administration and addressing adherence challenges in outpatient chemotherapy. Helsinn focuses on integrated supportive-care products and has a presence in palonosetron and other antiemetic classes that target 5‑HT3 pathways, complementing steroid and NK1 antagonist regimens favored in guideline-based prophylaxis. Novartis and its affiliated lines participate via branded and generic 5‑HT3 agents and supportive-care strategies, contributing to market breadth across hospital and retail channels and supporting combination regimen adoption.
Pfizer, Kyowa Kirin (and Ono as regional partners), Teva Pharmaceutical Industries, and Roche (including Sandoz/Generics affiliates) supply a mix of branded agents, generics, and hospital-focused formulations that sustain global access to CINV treatments. Pfizer’s broader oncology portfolio and acquisitions strengthen its role in supportive-care combinations and formulary presence, while Kyowa Kirin and Ono supply regionally significant antiemetics and collaborate on development of NK1/5‑HT3 combinations and novel delivery forms. Teva and Sandoz (Novartis’s generics arm) drive volume through ondansetron, granisetron, and other generic 5‑HT3 agents that lower cost barriers and enable guideline-concordant triple therapy in many health systems. Roche and its generics/partner channels play a complementary role by supplying IV formulations and hospital-oriented logistics that match oncology infusion workflows, supporting adoption of prophylactic regimens for highly and moderately emetogenic chemotherapy.
Emerging and specialty players such as Acacia Pharma, Camurus, and regional companies (Dr. Reddy’s, Sun Pharmaceutical, Aurobindo/Cipla, and Qilu) expand therapeutic options with novel formulations, transdermal systems, and targeted molecules that address breakthrough, delayed, and anticipatory CINV. Acacia’s IV amisulpride development and Camurus’s formulation work target refractory or rescue-use cases, while companies like Dr. Reddy’s, Sun Pharma, Aurobindo, and Cipla increase generic supply of 5‑HT3 antagonists and corticosteroids that underpin standard regimens in cost-sensitive markets. Startups and specialty biotech firms are also advancing non‑oral delivery (e.g., transdermal patches) and long‑acting depot approaches to reduce dosing complexity and improve multi‑day coverage, creating competitive pressure and partnership opportunities for incumbents across hospital, retail, and outpatient oncology settings.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.